Rachel Meyers Teriflunomide isn't the toughest comparator out there, would like to see how remibrutinib stacks up against some of the stronger existing MS drugs before getting too excited.
Marcus Bell million is a big bet on international distribution. Curious if that pays off faster than their usual timelines given how slow medtech rollouts can be.